XÁC ĐỊNH NGƯỠNG TỐI ƯU CỦA CHỈ SỐ TỶ SỐ BẠCH CẦU ĐA NHÂN TRUNG TÍNH VÀ TỶ SỐ TIỂU CẦU TRƯỚC ĐIỀU TRỊ TRONG TIÊN LƯỢNG ĐÁP ỨNG HÓA CHẤT Ở BỆNH NHÂN UNG THƯ PHỔI KHÔNG TẾ BÀO NHỎ GIAI ĐOẠN IV TẠI BỆNH VIỆN QUÂN Y 103

Abstract

Objectives: To determine the optimal cut-off values of pretreatment neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) in predicting platinum-based chemotherapy response in patients with stage IV non-small cell lung cancer (NSCLC). Methods: A retrospective, prospective, longitudinal, descriptive study was conducted on 92 patients with stage IV NSCLC treated with platinum-based chemotherapy at Military Hospital 103, from June 2020 to June 2025. Results: The non-response group had significantly higher NLR and PLR than the response group (6.72 vs. 3.75; 262.15 vs. 171.46; p < 0.01), while lymphocyte counts were lower (1.52 vs. 3.15 G/L; p < 0.01). ROC analysis showed that NLR had an AUC of 0.863 (95%CI: 0.756 - 0.970), with an optimal cut-off point of 4.02 (Se 77.3%; Sp 84.7%; p < 0.001). PLR had an AUC of 0.743 (95%CI: 0.607 - 0.880), with an optimal cut-off point of 164.8 (Se 75.6%; Sp 78.5%; p = 0.004). Other clinical and pathological factors, including age, sex, smoking status, ECOG PS, disease stage, histology, and EGFR mutation status, were not significantly associated with chemotherapy response. Conclusion: Pretreatment NLR and PLR were valuable predictors of response to platinum-based chemotherapy in stage IV NSCLC patients, with optimal cut-off values of 4.02 and 164.8, respectively.